Experienced in Metastatic Brain Tumor

Anna Laurell

Uppsala, C, SE 
Experienced in Metastatic Brain Tumor
Uppsala, C, SE 
OverviewLocationsClinical Research

Overview

Anna Laurell practices in Uppsala, Sweden. Ms. Laurell is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Testicular Cancer, Metastatic Brain Tumor, and Nephrectomy.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Metastatic Brain Tumor.

Gender
Female

Locations

Uppsala, C, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Cabazitaxel
Study Phase: Phase 2
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: April 24, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

27 Total Publications

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.
Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.
Journal: Acta oncologica (Stockholm, Sweden)
Published: August 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Laurell's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile